CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...
Recently, an alternative longer acting steroid, dexamethasone implant (Ozurdex), had been extensively studied and gained licensing for its efficacy in treating CRVO-ME. The Ozurdex trial compared ...
Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...
In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on CervoMed (CRVO – Research Report). The company’s shares opened today at $2.16. Effectively assess a stock's ...
Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback